The content on this site is intended for healthcare professionals only
Prof Siow Ming Lee presents IPSOS, a phase 3 study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC - not eligible for a platinum-containing regimen.
The results of trial showed 1L atezo improved OS vs chemo in platinum-ineligible pts with NSCLC, with twice as many pts estimated to be alive at 2 yr when treated with atezo vs chemo. Additionally, no new or unexpected safety concerns were seen in this poor prognosis population.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 4th - 10th, 2023
The current status of multiple myeloma diagnosis and treatment
Choosing Wisely in radiology Tanzania
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
